AU2022250867A1 - Anti-nectin-4-antibodies and uses thereof - Google Patents

Anti-nectin-4-antibodies and uses thereof Download PDF

Info

Publication number
AU2022250867A1
AU2022250867A1 AU2022250867A AU2022250867A AU2022250867A1 AU 2022250867 A1 AU2022250867 A1 AU 2022250867A1 AU 2022250867 A AU2022250867 A AU 2022250867A AU 2022250867 A AU2022250867 A AU 2022250867A AU 2022250867 A1 AU2022250867 A1 AU 2022250867A1
Authority
AU
Australia
Prior art keywords
seq
cdr
region
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022250867A
Other languages
English (en)
Inventor
Jack Elands
Florence LHOSPPICE
Marc Lopez
Daniel Olive
Xavier PRÉVILLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Institute Paoli-Calmettes
Eli Lilly and Co
Original Assignee
Aix-Marseille Université
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Institute Paoli-Calmettes
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21170941.5A external-priority patent/EP4066899A1/en
Priority claimed from EP21172723.5A external-priority patent/EP4086284A1/en
Application filed by Aix-Marseille Université, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institute Paoli-Calmettes, Eli Lilly and Co filed Critical Aix-Marseille Université
Publication of AU2022250867A1 publication Critical patent/AU2022250867A1/en
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D’AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –, EMERGENCE THERAPEUTICS GMBH reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Amend patent request/document other than specification (104) Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –, EMERGENCE THERAPEUTICS AG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D’AIX-MARSEILLE
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D’AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –, ELI LILLY AND COMPANY reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Request for Assignment Assignors: EMERGENCE THERAPEUTICS GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D’AIX-MARSEILLE
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022250867A 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof Pending AU2022250867A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21166441.2 2021-03-31
EP21166441 2021-03-31
EP21170941.5 2021-04-28
EP21170941.5A EP4066899A1 (en) 2021-03-31 2021-04-28 Anti-nectin-4 antibody
EP21172723.5 2021-05-07
EP21172723.5A EP4086284A1 (en) 2021-05-07 2021-05-07 Anti-nectin-4 antibody exatecan conjugates
EP21209332.2 2021-11-19
EP21209332 2021-11-19
PCT/EP2022/058626 WO2022207822A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2022250867A1 true AU2022250867A1 (en) 2023-08-03

Family

ID=80999114

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022250867A Pending AU2022250867A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof
AU2022248735A Pending AU2022248735A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022248735A Pending AU2022248735A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates

Country Status (18)

Country Link
US (4) US20240173424A1 (cg-RX-API-DMAC7.html)
EP (2) EP4314057A1 (cg-RX-API-DMAC7.html)
JP (2) JP7579991B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240028330A (cg-RX-API-DMAC7.html)
AU (2) AU2022250867A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017728A2 (cg-RX-API-DMAC7.html)
CA (2) CA3212655A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002907A1 (cg-RX-API-DMAC7.html)
CO (2) CO2023012821A2 (cg-RX-API-DMAC7.html)
CR (2) CR20230469A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000213A (cg-RX-API-DMAC7.html)
EC (2) ECSP23073625A (cg-RX-API-DMAC7.html)
IL (2) IL305954A (cg-RX-API-DMAC7.html)
JO (2) JOP20230238A1 (cg-RX-API-DMAC7.html)
MX (2) MX2023011563A (cg-RX-API-DMAC7.html)
PE (2) PE20240724A1 (cg-RX-API-DMAC7.html)
SA (1) SA523450918B1 (cg-RX-API-DMAC7.html)
WO (3) WO2022207822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
EP4725964A1 (en) * 2023-06-08 2026-04-15 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Antibody binding to nectin-4 and use thereof
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン-4抗体及び抗体-薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130088116A (ko) * 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
EP3546448B1 (en) * 2016-11-25 2022-04-06 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
US11274160B2 (en) * 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2020216947A1 (en) * 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020364959B2 (en) * 2019-10-07 2026-07-09 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for Nectin-4 and uses thereof
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Also Published As

Publication number Publication date
JP7579990B2 (ja) 2024-11-08
EP4314057A1 (en) 2024-02-07
JP2024515536A (ja) 2024-04-10
DOP2023000213A (es) 2024-04-30
CA3212651A1 (en) 2022-10-06
MX2023011563A (es) 2024-02-08
IL305951A (en) 2023-11-01
WO2022207825A1 (en) 2022-10-06
US20240181075A1 (en) 2024-06-06
BR112023019749A2 (pt) 2024-01-23
US20250018053A1 (en) 2025-01-16
US20240034791A1 (en) 2024-02-01
CL2023002909A1 (es) 2024-05-10
CO2023012828A2 (es) 2024-02-15
BR112023017728A2 (pt) 2023-11-21
JOP20230238A1 (ar) 2023-09-28
ECSP23073436A (es) 2024-02-29
AU2022248735A1 (en) 2023-08-03
ECSP23073625A (es) 2024-02-29
WO2022207822A1 (en) 2022-10-06
EP4262988A1 (en) 2023-10-25
JP7579991B2 (ja) 2024-11-08
SA523450918B1 (ar) 2025-05-07
CA3212655A1 (en) 2022-10-06
CR20230470A (es) 2023-11-30
JOP20230239A1 (ar) 2023-09-28
DOP2023000214A (es) 2024-04-30
US20240173424A1 (en) 2024-05-30
WO2022207828A1 (en) 2022-10-06
CL2023002907A1 (es) 2024-05-10
KR20240035378A (ko) 2024-03-15
MX2023011561A (es) 2024-02-08
PE20240725A1 (es) 2024-04-15
CO2023012821A2 (es) 2024-02-26
IL305954A (en) 2023-11-01
PE20240724A1 (es) 2024-04-15
JP2024520188A (ja) 2024-05-22
US12049500B2 (en) 2024-07-30
CR20230469A (es) 2023-11-30
KR20240028330A (ko) 2024-03-05

Similar Documents

Publication Publication Date Title
US12049500B2 (en) Anti-nectin-4-antibodies and uses thereof
CN105008398B (zh) 抗her2抗体及其缀合物
EP4039706A1 (en) Cldn18.2-targeting antibody, preparation method therefor, and use thereof
KR20230124037A (ko) 종양 특이적 claudin 18.2 항체-약물 접합체
JP2022551537A (ja) ネクチン-4に対する特異性を有する抗体及びその使用
EP4066899A1 (en) Anti-nectin-4 antibody
US20260062481A1 (en) Novel anti-nectin-4 antibodies and antibody-drug conjugates
EP4086284A1 (en) Anti-nectin-4 antibody exatecan conjugates
RS57120B1 (sr) Anti-humano dlk-1 antitelo koje ima in vivo aktivnost protiv tumora
EP4324849A1 (en) Humanized anti-nectin-4 antibodies
KR20180119676A (ko) 포도칼릭신 및 tra-관련된 항체, 생산 방법 및 항암 치료제로서의 용도
CN117440970A (zh) 抗nectin-4抗体及其用途
TW201922796A (zh) 可用於實體腫瘤治療之抗體及其抗體-藥物共軛物以及含其之抗癌劑
EP4309676A1 (en) Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4285935A1 (en) Novel anti-nectin-4 antibody camptothecin derivative conjugates
EA050098B1 (ru) Антитела к нектину-4 и их применение
EA049994B1 (ru) Конъюгаты антитела против нектина-4 и эксатекана
BR112023019749B1 (pt) Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos
EP4461317A1 (en) Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS AG; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: INSTITUT JEAN PAOLI & IRENE CALMETTES

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS AG; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS AG; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: UNIVERSITE D'AIX-MARSEILLE

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS AG; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: EMERGENCE THERAPEUTICS GMBH

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS AG; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

PC1 Assignment before grant (sect. 113)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: INSTITUT JEAN PAOLI & IRENE CALMETTES

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: UNIVERSITE D'AIX-MARSEILLE

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: ELI LILLY AND COMPANY

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -